Impact of TP53 Mutations on Outcome in EGFR -Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261

p53, the cellular gatekeeper for growth and division

Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489

Transcriptional control of human p53-regulated genes

Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Yang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, C., Hu, C.-P., O'Byrne, K., Feng, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71173-8 · Cited by 1,574

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

Pao, W. J., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G., & VARMUS, H. E. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020017 · Cited by 1,517

Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence

Mitsudomi, T., Kosaka, T., Endoh, H., Horio, Y., Hida, T., Mori, S., Hatooka, S., Shinoda, M., Takahashi, T., & Yatabe, Y. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.992 · Cited by 940

TP53 Mutations and Survival in Squamous-Cell Carcinoma of the Head and Neck

Poeta, M. L., Manola, J. B., Goldwasser, M. A., Forastiere, A. A., Benoit, N. E., Califano, J. A., Ridge, J. A., Goodwin, J. W., Kenady, D. E., Saunders, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073770 · Cited by 818

First-line Osimertinib for Lung Cancer With Uncommon EGFR Exon 19 Mutations and EGFR Compound Mutations

Cheunkarndee, T., Guo, M. Z., Houseknecht, S., Feliciano, J. L., Hann, C. L., Lam, V. K. L., Levy, B. P., Murray, J. C., Brahmer, J. R., Forde, P. M., et al. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100686 · Cited by 4

Impact of TP53 Co-Mutation on Clinicopathological Features, Prognosis, Recurrence Patterns, and the Efficacy of EGFR-TKI Treatment After Recurrence in Resected Early-Stage EGFR-Mutated Lung Adenocarcinoma

Masuda, T., Katsumata, S., Isaka, M., Serizawa, M., Kawata, T., 桃子, 浅., Yamaguchi, D., Matsushima, K., Hayasaka, K., Kojima, H., et al. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.04.009 · Cited by 3

Biological impact of chemotherapy during treatment with EGFR tyrosine kinase inhibitors for non-small cell lung cancer positive for EGFR activating mutations

Iwama, E., Sakai, K., Harada, T., Kanda, S., Sugawara, S., Yokoyama, T., Taniguchi, H., Tanaka, K., Toyozawa, R., Koyama, K., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108756 · Cited by 3

Circulating tumor DNA analysis in patients with EGFR mutant lung cancer

Nanjo, S., & Bivona, T. G. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.09.106 · Cited by 3

Postoperative adjuvant EGFR-TKIs for resected EGFR-mutant NSCLC—opportunities and obstacles

Parris, B. A., Leong, S. C., Marshall, H., Yang, I. A., Bowman, R., & Fong, K. M. (2021) · Annals of Translational Medicine · doi:10.21037/atm-2020-133 · Cited by 3

Intra-tumor and Inter-tumor Heterogeneity in MET Exon 14 Skipping Mutations and Co-mutations in Pulmonary Pleomorphic Carcinomas

Fujino, T., Suda, K., Sakai, K., Murakami, I., Shimizu, S., Ohara, S., Koga, T., Hamada, A., Soh, J., Nishio, K., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.09.005 · Cited by 3

Clinical Impact of Genomic and Pathway Alterations in Stage I EGFR-Mutant Lung Adenocarcinoma

Lee, J. S., Kim, E., Kim, K., & Shim, H. S. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2023.728 · Cited by 3

Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC

Tompkins, W. P., Grady, C. B., Hwang, W., Chandrasekhara, K., McCoach, C. E., Sun, F., Liu, G., Patel, D., Nieva, J. J., Herrmann, A. C., et al. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100669 · Cited by 3

Long-Term Outcomes in Patients with EGFR Positive Lung Adenocarcinoma and Subgroup Analysis Based on Presence of Liver Metastases

Krstić, V. Ć., Soldatović, I., Samardžić, N., Gajić, M., Kontić, M., Reljić, A., Savić, M., Milenković, M. R., & Jovanović, D. M. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46120801 · Cited by 3

EGFR status assessment using reflex testing targeted next-generation sequencing for resected non-squamous non-small cell lung cancer

Goffinet, S., Bontoux, C., Heeke, S., Pezzuto, F., Ilié, M., Long-Mira, É., Lassalle, S., Bordone, O., Lespinet‐Fabre, V., Allégra, M., et al. (2024) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-024-04010-4 · Cited by 3

Characterization of the genomic landscape in liver oligometastatic NSCLC

Liao, R., Yi, G., Shen, L., Xiao, X., Zeng, C., Liu, L., Tang, H., Huang, S., Zhang, X., Xu, Z., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-13478-5 · Cited by 3

Genomic Alteration Spectrum of Non-Small Cell Lung Cancer Patients in East-China Characterized by Tumor Tissue DNA and Cell-Free DNA

Li, J., Chen, S., Xue, H., Wang, H., Huang, T., Xie, H., He, J., Cai, K., Yu, Z., & Ni, B. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s351085 · Cited by 3

The impact of co-occurring tumor suppressor mutations with mEGFR as early indicators of relapse in lung cancer

Hait, S., Noronha, V., Chowdhury, R., Chaudhary, A. R. H., Bawaskar, B., Dahimbekar, G., Ahmad, S., Joshi, A., Patil, V., Menon, N. S., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.104479 · Cited by 2

Revisiting p53 Immunohistochemical Staining and Its Prognostic Implications in Advanced EGFR-Mutated Lung Adenocarcinoma

Kuan, F., Chang, S., Yang, Y.-R., Wu, Y.-Y., Chen, F., Lee, K.-F., Chi, C.-L., Lin, M., & Shi, C. (2025) · Cancers · doi:10.3390/cancers17213577 · Cited by 2

TP53 Functional-Domain-Specific Mutations Define Distinct Clinical Outcomes in EGFR-Mutant Non-Small Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors

Kobayashi, K. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15041552 · Cited by 2

Diverse genomic and transcriptomic heterogeneity in EGFR-mutant lung adenocarcinoma between exon 19 del and exon 21 L858R

Yang, Y., Qiao, S., Sun, D., Zhang, Z., Zhao, Y., Zhan, J., Huang, Y., Zhao, H., Yang, Y., Wu, K., et al. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02793-4 · Cited by 2

Genomic characterization of DNA damage response pathway mutations reveals their adverse impact on EGFR-TKI efficacy in non-small cell lung cancer

Yang, L., Cheng, J., Guo, X., Xiao, H., Kuang, X., Yang, Y. S., Zhang, L., Zhang, Q., Wang, D., Xu, Y., et al. (2026) · Respiratory Research · doi:10.1186/s12931-026-03699-y · Cited by 2

Effect of Smoking Status on the Efficacy of EGFR-TKI Plus Anti-Angiogenic Agent in Advanced EGFR-Mutant NSCLC

Qin, B., Jiao, X., Wang, Y., Wu, Y. X., Ling, Y., Liu, K., & Zang, Y. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.06.006 · Cited by 2

Clinical and Genomic Analysis of Patients with Short Survival after Surgery for Esophageal Squamous Cell Carcinoma

Gao, L., Guo, R.-Y., Lu, H., Shi, Z., & Liu, J. (2022) · Digestive Diseases · doi:10.1159/000527983 · Cited by 2

TARGETED THERAPY OF ANAPLASTIC THYROID CANCER

Kononenko, M. G., Duzhiy, I., & Moskalenko, Y. (2023) · Eastern Ukrainian Medical Journal · doi:10.21272/eumj.2023;11(2):113-120 · Cited by 2

Germline potential should not be overlooked for cancer variants identified in tumour-only somatic mutation testing

Al-Shinnag, M., Cheong, P. L., Goodwin, A., Trent, R. J., & Yu, B. (2024) · Pathology · doi:10.1016/j.pathol.2024.03.001 · Cited by 2

Negative-predictive value of SUVmax for Ascertaining the efficacy of osimertinib in EGFR mutation-positive non-small cell lung cancer

Anai, M., Inoue, H., Saruwatari, K., Oda, S., Shiraishi, S., Akaike, K., Imamura, K., Jodai, T., Sakata, S., Iyama, S., et al. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.09.001 · Cited by 2

[Genetic Profile of Young Chinese Patients with Lung Adenocarcinoma].

Yu, L., Hou, H., Jiang, M., Zhang, C., Liu, D., & Zhang, X. (2020) · PubMed Central · doi:10.3779/j.issn.1009-3419.2020.101.17 · Cited by 2

4-Acetylantrocamol LT3 Inhibits Glioblastoma Cell Growth and Downregulates DNA Repair Enzyme O6-Methylguanine-DNA Methyltransferase

Lee, S., Yen, I., Lin, J., Chung, M.-C., & Liu, W. (2021) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x21500476 · Cited by 2

[Research Advances of EGFR-TP53 Co-mutation in Advanced Non-small Cell Lung Cancer].

Wang, R., Pan, S., & Song, X. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.101.06 · Cited by 2

Dacomitinib overcomes acquired resistance to osimertinib in advanced NSCLC patients with EGFR L718Q mutation: A two-case report

li, J., Jin, M., Diao, Y., & Li, X. (2024) · Medicine · doi:10.1097/md.0000000000038789 · Cited by 2

First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation

Xiong, Y., Wang, L., Zhang, W., Meng, Y., Wang, Y., Shen, M., Zhou, L., Li, R., Lv, Y., Wang, S., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-13084-x · Cited by 2

Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC

Liao, B.-C., Hsu, W., Lee, J., Yang, C., Tsai, T.-H., Liao, W., Ho, C., Lin, C., Shih, J., Yu, C., et al. (2020) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100099 · Cited by 2

Frequencies of TP53 Germline Variations and Identification of Two Novel 3’UTR Variants in a Series of Head and Neck Cancer CasesPreprint

Ajaz, S., Muneer, R., Siddiqa, A., & Memon, M. A. (2021) · medRxiv · doi:10.1101/2021.09.09.21263314 · Cited by 2

TP53 Loss of Heterozygosity Induces De Novo SCLC Formation in EGFR-Mutated Lung Adenocarcinoma: A Case Report

Kunimasa, K., Hirotsu, Y., Amemiya, K., Nakamura, H., Nishino, K., Honma, K., Okami, J., Omata, M., & Kumagai, T. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100305 · Cited by 1

Detection and monitoring of driver mutations by next‐generation sequencing in squamous cell lung cancer patient and possible predictive biomarker of third generation EGFR‐tyrosine kinase inhibitors

Shen, X., Shen, J., Zhang, H., Cheng, Y., Yang, Y., Gao, J., Zhang, Y., Li, R., Liu, B., & Wang, L. (2017) · Thoracic Cancer · doi:10.1111/1759-7714.12551 · Cited by 1

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with recurrent non-small cell lung cancer after definitive concurrent chemoradiation or radiotherapy

Hyung, J., Yoon, H., Choi, C., Yoon, S., Lee, K. H., Kim, S., Kim, H.-R., Kim, S. S., Song, S. Y., & Lee, J. C. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04287-5 · Cited by 1

Correlation analysis of EGFR gene mutation abundance and the efficacy of targeted therapy with osimertinib in nonsmall cell lung cancer—a case control study

Yan, H., Peng, J., Wang, Z., Chen, H., & He, C. (2024) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231224372 · Cited by 1

Efficacy of ramucirumab combined with erlotinib or osimertinib in untreated EGFR-mutated NSCLC patients with asymptomatic brain metastases: insights from molecular biomarkers in the RELAY-brain trial

Kaneda, H., Daga, H., Okada, A., Nakatani, Y., Tani, Y., Oka, T., Sawa, K., Sakai, K., Nishio, K., & Kawaguchi, T. (2025) · Investigational New Drugs · doi:10.1007/s10637-025-01505-y · Cited by 1

The effectiveness of sequential afatinib and furmonertinib in an advanced lung adenocarcinoma with rare compound EGFR mutation (L833V/H835L)

Pan, Y., Yan, L., Gu, Y., Wang, S., Li, H., Yu, P., & Chen, Q. (2025) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001692 · Cited by 1

Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review

Lin, R., Chen, R., Chen, Z., Hu, L., Guo, W., Zhang, Z., Lin, L., & Chen, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.731572 · Cited by 1

[Clinical Characteristics and Prognosis of 76 Lung Adenocarcinoma Patients Harboring EGFR Mutations with Pleural Effusion at Initial Diagnosis: A Single-center Retrospective Study].

Yin, W., Zhang, H., Gu, Y., Yi, F., Li, Q., Liu, Y., Yao, Y., Liu, Z., & Cao, B. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.101.13 · Cited by 1

The reality of complexity: concomitant genomic alterations in patients with EGFR mutations

Cardona, A. F., Zatarain-Barrón, Z. L., Rojas, L., & Arrieta, O. G. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.12.136 · Cited by 1

Response to: The Role of Dual Inhibition of EGFR and Vascular EGF(R) in the Treatment of NSCLC With EGFR Mutation

Zhao, H., Zhang, Z., & Zhang, L. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.013 · Cited by 1

LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS -mutant lung cancersPreprint

Li, C., Syed, M. U., Nimbalkar, A., Shen, Y., Fraser, C., Inde, Z., Qin, X., Ouyang, J., Kreuzer, J., Clark, S. E., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.29.510137 · Cited by 1

Tobacco smoke alters the trajectory of lung adenocarcinoma evolution via effects on somatic selection and epistasisPreprint

Dasari, K., Alfaro-Murillo, J. A., & Townsend, J. P. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.27.625765 · Cited by 1

Molecular Divergence upon EGFR-TKI Resistance Could Be Dependent on the Exon Location of the Original EGFR-Sensitizing Mutation

Serna‐Blasco, R., Sánchez‐Herrero, E., de Lope, L. R., Sanz‐Moreno, S., Rodríguez-Festa, A., Trotta, D. A., Cruz‐Bermúdez, A., Franco, F., Sánchez-Hernández, A., Campayo, M. D. J., et al. (2022) · Cancers · doi:10.3390/cancers14184446

Clinicopathologic and Molecular Subtyping of EGFR Mutation—Response

Jung, H. A., Lim, J., Choi, Y., Kim, J., & Park, K. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3549

Additional file 1 of Genomic features and its potential implication in bone oligometastatic NSCLC

Liao, R., Yi, G., Shen, L., Zhang, X., Xu, Z., Peng, Y., & Yang, Z. (2023) · Figshare · doi:10.6084/m9.figshare.22609952

Additional file 3 of Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study

Lu, C. F., Dong, X., Zhao, J., Zhang, X., Chen, H., Zhou, Q. H., Tu, H., Ai, X., Chen, X.-F., An, G., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12134448

Additional file 1 of Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study

Lu, C. F., Dong, X., Zhao, J., Zhang, X., Chen, H., Zhou, Q. H., Tu, H., Ai, X., Chen, X., An, G., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12134427

Clinicopathological and molecular characterization of resected lung adenocarcinoma: Correlations with histopathological grading systems in Chinese patients

Xia, W., Zhang, S., Ye, Y., Han, X., Zhang, Y., Ning, G., Zhang, Y., Wang, W. J., & Fei, G. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155359

Osimertinib plus Chemotherapy versus Osimertinib for Patients with Advanced NSCLC Concomitant EGFR and TP53 Mutations: A Prospective Cohort StudyPreprint

Li, J., Zhan, X., Shao, M., Zeng, R., Li, J., Zhu, H., Feng, A., Yang, Z., & Jing, W. (2024) · Research Square · doi:10.21203/rs.3.rs-4467606/v1

Case Report: A novel MET exon 14 skipping mutation after EGFR-TKI resistance in advanced lung adenocarcinoma and sustained clinical response to savolitinib

Xue, Y., Li, W., Li, P., Huang, K., Zhou, Q., & Wu, Q. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1489696

Biological Impact of Chemotherapy During Treatment with Egfr Tyrosine Kinase Inhibitors for Non-Small Cell Lung Cancer Positive for Egfr Activating MutationsPreprint

Iwama, E., Sakai, K., Harada, T., Kanda, S., Sugawara, S., Yokoyama, T., Taniguchi, H., Tanaka, K., Toyozawa, R., Koyama, K., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5347261

Evaluation of PD-L1 Expression and Anti-EGFR Therapy in EGFR-Mutant Non-Small-Cell Lung Cancer

Teoman, G., Karaman, E., Ersöz, Ş., & Munğan, S. (2025) · Medicina · doi:10.3390/medicina61081467

Mutational landscape and tyrosine kinase inhibitor sensitivity in EGFR L833 and H835 mutated non–small cell lung cancer

Huang, L., Zeng, F., Huang, P., Ren, D., Liu, Z., Chen, H., Wu, X., Pang, J., Ou, Q., Zhao, X., et al. (2025) · Cancer · doi:10.1002/cncr.70063

Cells of Origin and Tumor Heterogeneity in Lung Cancer Guide Personalized Therapeutic StrategiesPreprint

Liang, J., Liu, Y., Teng, X., Zhao, Y. Q., Zeng, J., Ning, W., Xu, Z., Zhao, J., Yao, M., Tang, J., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7441718/v1

Identification of internalizing ScFvs for EGFR inhibition and apoptosis induction in cholangiocarcinoma cells

Sayinta, A., Duangdara, J., Sumphanapai, T., Rangnoi, K., Boonsri, B., Supradit, K., Jongkamonwiwat, N., Choowongkomon, K., Thitapakorn, V., Yamabhai, M., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-24324-w

Additional file 9 of Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

Qin, K., Helei, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144525

Additional file 1 of Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study

Sun, H., Ren, P., Chen, Y., Lan, L., Yan, Z., Yang, Y., Wang, B., Wang, C., Li, Y., Li, L., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22606069

Additional file 2 of Genomic features and its potential implication in bone oligometastatic NSCLC

Liao, R., Yi, G., Shen, L., Zhang, X., Xu, Z., Peng, Y., & Yang, Z. (2023) · Figshare · doi:10.6084/m9.figshare.22609955

Additional file 4 of Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

Qin, K., Helei, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144495

Additional file 7 of Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

Qin, K., Helei, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144510

Additional file 1 of Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

Qin, K., Helei, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144483

Additional file 6 of Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

Qin, K., Helei, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144501

Additional file 2 of Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

Qin, K., Helei, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144486

Additional file 11 of Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

Qin, K., Helei, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144480

Additional file 4 of Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study

Lu, C., Dong, X.-R., Zhao, J., Zhang, X.-C., Chen, H.-J., Zhou, Q., Tu, H.-Y., Ai, X., Chen, X.-F., 安改丽, et al. (2020) · Figshare · doi:10.6084/m9.figshare.12134454

Additional file 3 of Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

Qin, K., Helei, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144489

Additional file 2 of Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study

Lu, C., Dong, X.-R., Zhao, J., Zhang, X.-C., Chen, H.-J., Zhou, Q., Tu, H.-Y., Ai, X.-H., Chen, X.-F., 安改丽, et al. (2020) · Figshare · doi:10.6084/m9.figshare.12134436

Additional file 5 of Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

Qin, K., Hou, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144498

Additional file 1 of Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non–small-cell lung cancer with an EGFR/TP53 co-mutation

Shang, K., Huang, H., Xu, Y., Liu, Y., Lu, Z., & Chen, L. (2024) · Figshare · doi:10.6084/m9.figshare.26553026

Additional file 10 of Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

Qin, K., Hou, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144474

Additional file 8 of Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

Qin, K., Hou, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144516

Additional file 1 of Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study

Zhang, Y., Zhang, X., Zhang, R., Xu, Q., Yang, H., Lizaso, A., Xu, C., Liu, J., Wang, W., Ou, S.-H. I., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16608932

Additional file 2 of Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study

Zhang, Y., Zhang, X., Zhang, R., Xu, Q., Yang, H., Lizaso, A., Xu, C., Liu, J., Wang, W., Ou, S.-H. I., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16608935

Efficacy and Safety of Combined Anlotinib and Icotinib in EGFR-Mutant Advanced Non-Squamous NSCLC: Final Analysis of a Prospective Phase II Study

Martinez, A. B., & Santos, L. M. (2024) · Asian journal of Current Research in Clinical Cancer · doi:10.51847/gf6r5pergp

Integrative learning of linear non-Gaussian directed acyclic graphs with application on multisource gene regulatory network analysis

Li, X., Zhang, S., Mingyang, R., & Zhang, Q. (2026) · The Annals of Applied Statistics · doi:10.1214/25-aoas2116

Évaluation du patrimoine tumoral circulant dans la prise en charge thérapeutique des patients atteints de cancer broncho-pulmonaire

Garcia, J. (2019) · theses.fr (ABES) · doi:10.70675/f648973az2136z4580z91b5z75a3710f1907

Prognostic significance of RICTOR mutations in EGFR-mutant metastatic lung adenocarcinoma: a retrospective cohort study

AYTAÇ, A., Özata, M., Erdoğdu, İ. H., Alkan, A., & Tanrıverdi, Ö. (2026) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-026-04559-2

DNA Single Nucleotide Polymorphism (SNP) Analysis

Zhang, P. (2026) · Springer eBooks · doi:10.1007/978-981-95-7295-3_8

Paired ctDNA analysis reveals diverse resistance mechanisms to mobocertinib in EGFR exon 20 insertion NSCLC

Kim, J., Park, G., Park, S., Jung, H. A., Lee, S.-H., Ahn, J. S., Ahn, M., & Sun, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1827867

Acquired ROS1 Intragenic Rearrangements as a Resistance Mechanism in EGFR-Mutant Non-Small Cell Lung Cancer: A Case Series

Liu, P., Chen, Y., Chen, W.-L., Ho, C., & Lee, C.-H. (2026) · Current Oncology · doi:10.3390/curroncol33060311

Role of VEGFA/VEGFR2 signaling in predicting clinical outcomes of EGFR-TKI treatment in EGFR-mutant non-small cell lung cancer

Higashiyama, R., Yoshida, T., Shiraishi, K., Miyakoshi, J., Torasawa, M., Shirasawa, M., Masuda, K., Shinno, Y., Matsumoto, Y., Okuma, Y., et al. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03457-3

Effect of EGFR-TP53 co-mutation on the efficacy of EGFR-TKIs in patients with advanced NSCLC and therapeutic strategies: A retrospective study

Feng, X., & Liu, L. (2026) · Medicine · doi:10.1097/md.0000000000049446

Genetic landscape features associated with PD-L1 expression status in advanced lung adenocarcinoma: a targeted sequencing analysis

Huang, M., Yao, Z., Zhang, H., Song, C., Wang, M., Zhao, J., Ji, S., Zhu, K., Zhao, M., & Zhang, D. S. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1892351

Concurrent loss of RB1 facilitates EGFR-TKI resistance in EGFR-mutant lung cancer by modulating histone crotonylation

Chen, S., Wang, X., Xuan, Q., Liu, C., Su, Y., Liu, Z., Jia, L., Ren, Y., Cui, W., Fan, X., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.08.007

Medicarpin triggers Fas cell surface death receptor-mediated apoptosis by inhibiting epidermal growth factor receptor/signal transducer and activator of transcription 3 pathway and protective autophagy in liver cancer

Yong-Zhuo, L. I., HUANG, C.-P., Li, J., Wang, J.-J., Yan, J., Liu, Z.-J., Ji, F., Yang, X.-M., Huang, X., Cui, J., et al. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158703

Is There Still Room for Monotherapy in EGFR -Mutated Non–Small Cell Lung Cancer?

Borgeaud, M., Lu, S., & Addeo, A. (2026) · JAMA · doi:10.1001/jama.2026.13325

Three-year adjuvant treatment of icotinib in stage II-IIIA EGFR-mutated lung adenocarcinoma (ICWIP): a randomized, double-blind, placebo-controlled phase 3 trial

Liu, Y., Tang, L., Han, X.-H., Song, Z.-Y., Liu, D.-R., Cheng, G., Xiao, W.-H., Zhang, S., Hu, Y., Zhang, L., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02994-w

Oncogene Driver Status Modulates TP53 Prognostic Impact in Advanced NSCLCPreprint

Pan, M., Jiang, C., Song, J., Kudrimoti, S., Aredo, J. V., Wakelee, H. A., Neal, J. W., Zhao, J., Kamgarhaghighi, Y., Achacoso, N. S., et al. (2026) · medRxiv · doi:10.64898/2026.09.04.26362258

A multicenter phase Ⅱ study of osimertinib plus infliximab in patients with EGFR-mutated non-small cell lung cancer positive for TP53 gain-of-function mutation who developed resistance to osimertinib (REGAIN trial)

Iwama, E., Tanaka, H., Shukuya, T., Daga, H., Takeda, M., Tanaka, K., Miyauchi, E., Fujiwara, Y., Ishikawa, N., Azuma, K., et al. (2026) · International Journal of Lung Cancer · doi:10.1016/j.ijlcan.2026.100066

Beyond Exons 19 and 21: mapping the clinical and molecular diversity of uncommon EGFR mutations in a Brazilian NSCLC cohort

de Sousa, J. C., Nogueira, C., Veloso, G. D. S., da Silva, E. L., Alves, M. S., Nasser, F., Neto, F. M., Ornellas, A. C. P., Nascimento, E., & Tavora, F. R. F. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101444

Co-mutation patterns and survival associations in lung cancer: a comparative analysis of Swedish and global cohorts

Karlowatz, N., Kohn, L., Patthey, C., Nilsson, J. A., & Johansson, M. (2026) · Acta Oncologica · doi:10.2340/1651-226x.2026.46330

Genomic co-alteration patterns are associated with differential benefit from first-line third-generation EGFR-TKI plus chemotherapy versus TKI monotherapy in advanced EGFR-mutant NSCLC

柏丽丽, Wu, H., Jiang, Y., Ran, D., Li, Y., Zhou, J., & Duan, T. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1969669

Role of TP53 mutations in predicting response to TKI treatment in EGFR-mutated NSCLC patients.

Ulivi, P., Canale, M., Petracci, E., Chiadini, E., Dazzi, C., Capelli, L., Gamboni, A., Casanova, C., Papi, M., Mariotti, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.9052 · Cited by 4

Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs

Canale, M., Petracci, E., Delmonte, A., Bronte, G., Chiadini, E., Ludovini, V., Dubini, A., Papi, M., Baglivo, S., Luigi, N. D., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041047 · Cited by 76

P3.02b-006 Role of TP53 Mutations in Determining Primary Resistance to First-Line Tyrosine Kinase Inhibitors in EGFR-Mutated NSCLC Patients

Ulivi, P., Canale, M., Delmonte, A., Petracci, E., Chiadini, E., Dazzi, C., Papi, M., Capelli, L., Casanova, C., Luigi, N. D., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.1673

TP53 mutations predicts worse prognosis in EGFR-mutated NSCLC patients receiving TKIs in first- or further line of treatment

Canale, M., Luigi, N. D., Petracci, E., Delmonte, A., Ludovini, V., Dubini, A., Baglivo, S., Minenza, E., Chiadini, E., Landi, L. M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz260.056

Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC

Hou, H., Qin, K., Yu, L., Zhang, C., Liu, D., Jiang, H., Liu, K., Zhu, J., Lv, H., Li, T., et al. (2019) · Cancer Management and Research · doi:10.2147/cmar.s201513 · Cited by 78